The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Central Nicotinic Receptors: Structure, Function, Ligands, and Therapeutic Potential
Abstract
The growing interest in nicotinic receptors, because of their wide expression in neuronal and non‐neuronal tissues and their involvement in several important CNS pathologies, has stimulated the synthesis of a high number of ligands able to modulate their function. These membrane proteins appear to be highly heterogeneous, and still only incomplete information is available on their structure, subunit composition, and stoichiometry. This is due to the lack of selective ligands to study the role of nAChR under physiological or pathological conditions; so far, only compounds showing selectivity between α4 β 2 and α 7 receptors have been obtained. The nicotinic receptor ligands have been designed starting from lead compounds from natural sources such as nicotine, cytisine, or epibatidine, and, more recently, through the high‐throughput screening of chemical libraries. This review focuses on the structure of the new agonists, antagonists, and allosteric ligands of nicotinic receptors, it highlights the current knowledge on the binding site models as a molecular modeling approach to design new compounds, and it discusses the nAChR modulators which have entered clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Neuronal nicotinic receptors: from structure to pathology
Gotti, C., & Clementi, F. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.09.006 · Cited by 970
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Bartus, R. T. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7397 · Cited by 829
Varenicline Is a Partial Agonist at α4β2 and a Full Agonist at α7 Neuronal Nicotinic Receptors
Mihalak, K. B., Carroll, F. I., & Luetje, C. W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025130 · Cited by 558
Effect of nicotine and nicotinic receptors on anxiety and depression
Picciotto, M. R., Brunzell, D. H., & Caldarone, B. J. (2002) · Neuroreport · doi:10.1097/00001756-200207020-00006 · Cited by 483
Nicotinic receptors in the brain. Links between molecular biology and behavior
Picciotto, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00146-3 · Cited by 354
Nicotinic acetylcholine receptors as targets for antidepressants
Shytle, R. D., Silver, A. A., Lukas, R. J., Newman, M. B., Sheehan, D. V., & Sanberg, P. R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001035 · Cited by 279
Picciotto, M. R., Caldarone, B. J., Brunzell, D. H., Zachariou, V., Stevens, T. R., & King, S. L. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00161-9 · Cited by 221
Glick, S. D., Maisonneuve, I. M., Kitchen, B. A., & Fleck, M. W. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01284-0 · Cited by 122
Gatto, G. J., Bohme, G. A., Caldwell, W. S., Letchworth, S. R., Traina, V. M., Obinu, M. C., Laville, M., Reibaud, M., Pradier, L., Dunbar, G., et al. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00010.x · Cited by 111
Rueter, L. E., Anderson, D. J., Briggs, C. A., Donnelly‐Roberts, D. L., Gintant, G. A., Gopalakrishnan, M., Lin, N., Osinski, M. A., Reinhart, G. A., Buckley, M. J., et al. (2004) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2004.tb00011.x · Cited by 70
Nicotinic cholinergic antagonists: A novel approach for the treatment of autism
Lippiello, P. M. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2005.11.015 · Cited by 43
Cited by
Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system
Taly, A., Corringer, P.-J., Guedin, D., Lestage, P., & Changeux, J.-P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2927 · Cited by 703
Nicotine binding to brain receptors requires a strong cation–π interaction
Xiu, X., Puskar, N. L., Shanata, J. A. P., Lester, H. A., & Dougherty, D. A. (2009) · Nature · doi:10.1038/nature07768 · Cited by 363
The structural basis of function in Cys-loop receptors
Thompson, A. J., Lester, H. A., & Lummis, S. C. R. (2010) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583510000168 · Cited by 341
Allosteric modulation of nicotinic acetylcholine receptors
Bertrand, D., & Gopalakrishnan, M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.011 · Cited by 255
Depressive symptoms predict clinical recurrence of inflammatory bowel disease
Jordi, S. B. U., Lang, B. M., Auschra, B., von Känel, R., Biedermann, L., Greuter, T., Schreiner, P., Rogler, G., Krupka, N., Sulz, M. C., et al. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab136 · Cited by 41
Metadata
- Authors
- Romanelli, M. N., Gratteri, P., Guandalini, L., Martini, E., Bonaccini, C., & Gualtieri, F.
- Venue
- ChemMedChem
- Publisher
- Wiley
- Published
- 2007-05-31
- Volume
- 2
- Issue
- 6
- Pages
- 746-767
- ISSN
- 1860-7179 (ISSN-L)
- 1860-7187
- OpenAlex
- W2166403013
- Cited by
- 162
- References
- 13
- FWCI
- 7.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.